BACKGROUND: Recent studies show an increased adipose production of tumor necrosis factor-alpha (TNF-a) in human obesity. It was hypothesized from this ®nding and other data, that TNF-a may be a mediator of obesity-linked insulin resistance. OBJECTIVE: The aim of this study was to measure plasma concentrations of the two soluble TNF-a receptors, together with those of TNF-a in subjects with severe obesity with and without type 2 diabetes mellitus, in comparison to a lean control group, to examine whether plasma concentrations re¯ect an up-regulation of the TNF system in adipose tissue. PATIENTS AND METHODS: Plasma concentrations of the two soluble TNF-a receptors were measured in 49 obese subjects (mean body mass index (BMI): 44.9 kgam 2 , 95% con®dence intervals (CI) 42.3 ± 47.5 kgam 2 , including 19 type 2 diabetic individuals) and 28 lean controls, by using a highly sensitive enzyme-linked immunoassay (ELISA) technique. TNF-a concentrations were determined in 28 obese (10 with diabetes) and 23 lean subjects. RESULTS: The obese subjects showed signi®cantly higher plasma concentrations of the soluble p60 and p80 TNF receptor, respectively, compared to the lean control group, independent of the presence of diabetes. Multiple regression analysis, with the p80 TNF receptor as dependent variable, revealed that BMI and log insulin signi®cantly affected the plasma concentration of this soluble receptor subtype, explaining 46% of the variance, whereas for the p60 TNF receptor, only BMI turned out to in¯uence plasma concentrations. TNF-a plasma concentrations were not different between the three groups (Kruskal-Wallis test: P 0.34), but due to the low power of the test, an effect of obesity on TNF-a is not excluded. CONCLUSION: These data indicate that plasma concentrations of both soluble TNF receptors are elevated in obesity and insulin resistance, possibly as a function of excess body fat. The reported adipose overexpression of TNF-a does not seem to be re¯ected by elevated plasma concentrations, suggesting a primarily local role of the cytokine.
Introduction
Recent studies suggest that tumor necrosis factoralpha (TNF-a) is expressed in adipose tissue 1 and that adipose expression of this cytokine is elevated in human obesity. 2, 3 There is some evidence that TNF-a can induce insulin resistance and may be at least partially responsible for the disturbances of glucose and lipid metabolism associated with obesity and type 2 diabetes mellitus. 4 For example, it is obvious from a number of studies, that TNF-a is able to directly interfere with early steps of the insulin signaling pathway. 5 ± 9 However, the results of other studies questioned the claimed role of TNF-a in the pathogenesis of insulin resistance. 10, 11 Experiments in cultured human fat cells also indicated that TNF-a can prevent adipose cell development and impair metabolic functions by multiple mechanisms. 12, 13 A recent study showed that TNF-a acutely inhibits insulin signaling in human adipocytes at the level of phosphatidylinositol 3-kinase and provided evidence that the p80 TNF receptor is involved in the development of insulin resistance. 9 In addition, recent data suggest that at least the p80 TNF receptor subtype is overexpressed in obesity and type 2 diabetes, 14, 15 probably contributing to the catabolic effects of TNF-a in these metabolic disorders. Extracellular TNF-a originates from a membrane-bound 26 kD precursor protein (mTNF) with full biological activity, which is proteolytically cleaved into its ®nal soluble form. Likewise, the two soluble receptor subtypes are shed from the plasma membrane as truncated forms. 16 Since adipose tissue plays only a minor role in glucose metabolism, relative to muscle, it remains an important question whether increased expression of TNF-a and its receptors in adipose tissue may elevate plasma levels of these components and, thereby, in¯uence insulin sensitivity in other organs. To address this question, we measured plasma levels of TNF-a and its two soluble receptors in de®ned groups, characterized by either obesity alone or obesity and non-insulin-dependent diabetes mellitus (NIDDM) as well as in a lean control group.
Patients and methods
A group of 49 severely obese subjects were included in the study. They were recruited between January and June 1996, from patients who were admitted to the Surgical Department of the Dominikus-Hospital Du Ès-seldorf-Heerdt, to undergo gastroplasty for surgical treatment of morbid obesity. 19 patients had either a history of type 2 diabetes or were identi®ed as having overt diabetes by an oral glucose tolerance test (OGTT) according to the World Health Organisation (WHO) recommendations, as this diagnostic test was routinely performed in all obese patients. 17 Those obese with known diabetes, were treated either by diet alone or by a combination of diet and oral antidiabetic agents, none required insulin. 28 lean subjects served as a control group. Lean subjects with a history of diabetes or laboratory ®ndings indicative of diabetes, were excluded. All subjects were otherwise healthy, according to history, clinical examination and routine laboratory ®ndings. In particular, subjects with evidence of acute or chronic in¯ammatory diseases were excluded. All subjects gave their informed consent to participate in this study.
Blood samples were collected in the morning between 07.00±09.00 h, after an overnight fast. Plasma samples were obtained by centrifugation at 4 C and were stored as aliquots at 720 C for later analysis. Body weight was measured to the nearest 0.5 kg, height to the nearest cm. The body mass index (BMI) was calculated as a measure of the degree of body fat. The waist circumference was measured midway between the lower rib margin and the iliac crest, the hip circumference over the buttocks. The waist-to-hip ratio (WHR) was used as a measure of the pattern of body fat distribution.
Laboratory tests
To exclude subjects with acute or chronic infections, a white blood cell count was performed and C-reactive protein was determined. Only subjects with values in the normal range were recruited. Plasma concentrations of the soluble p60 and p80 TNF receptor, respectively, were analysed by commercially available ELISAs (R&D Systems Inc., Minneapolis, MN). The minimum detectable concentration was`1.5 pgaml for the p60 TNF receptor and`1.0 pgaml for the p80 TNF receptor, respectively. The intra-and interassay coef®cients of variation for the soluble p60 TNF receptor were 2.2% and 4.1%, respectively, those for the soluble p80 TNF receptor were 4.1% and 6.1%, respectively. TNF-alpha in plasma was measured using a commercially available highly sensitive ELISA (R&D Systems Inc.) according to the instructions of the manufacturer. The minimum detectable concentration was in the range of 0.15 pgaml, the intraand interassay coef®cients of variation were 5.6% and 7.5%, respectively. Insulin was determined by radioimmunoassay (RIA, Sorin, Gif-sur-Yvette, France) and fasting triglycerides by an established enzymatic procedure using a commercially available test kit (Boehringer Mannheim, Mannheim, Germany).
Statistical analysis
Patient characteristics are described by frequency distribution or mean and 95% con®dence interval (CI). Geometric mean and the corresponding 95% CI is presented for variables, which were assumed to be log-normal distributed. Furthermore, the distribution of TNF-a is given by median, together with the 25 and 75 percentile. Statistical comparison between the three groups were performed by Fisher's exact test (gender) and by analysis of variance, including Fisher's least-signi®cant test (age, BMI, log fasting insulin, log fasting triglycerides, p60 and p80 soluble receptor). Median differences of TNF-a between the groups were statistically tested by the non-parametric Kruskal-Wallis test. P-values`0.05 were regarded as signi®cant.
Multiple linear regression models were ®tted to estimate the role of gender, age, BMI, diabetes, log fasting insulin, log fasting triglycerides, as prognostic factors for the p60 and p80 TNF receptor plasma concentration as dependent variable, respectively. Only the factors remaining after stepwise selection of variables are demonstrated. Linear dependencies between TNF-a and both TNF receptors were estimated by Pearson correlation coef®cients. All statistical calculations were carried out using the Statistical Analysis System software (SAS Version 6.12, SAS Institute, Cary, NC).
Results
The main characteristics of the three study groups are presented in Table 1 . Both groups of obese subjects had signi®cantly higher fasting insulin and triglyceride concentrations than the lean control group. Log transformed fasting triglycerides were signi®cantly higher in the obese subjects with diabetes, than those in the obese individuals without diabetes (P`0.05).
Plasma concentrations of the soluble TNF receptors were signi®cantly higher in both obese groups, compared to the lean control group. However, comparison of soluble TNF receptor concentrations between the obese and the obese type 2 diabetic group, did not show signi®cant differences (Figure 1 ). On average, mean plasma concentrations of both soluble receptors (Soluble) 
in the obese subjects were by 35±40% higher than in the lean controls.
In a multiple regression analysis combining the three groups with plasma concentration of the soluble p80 TNF receptor protein as dependent variable, it turned out that BMI (P`0.01) and log fasting insulin (P 0.07) independently affected circulating p80 TNF receptor concentrations and explained 46% of the variance, indicating that higher values of BMI and fasting insulin correspond to higher values of the soluble p80 TNF receptor protein ( Table 2 ). The result of the multiple regression analysis for the p60 TNF receptor as dependent variable is presented in Table 3 . Only BMI proved to be a signi®cant prognostic factor and predicted 38% of the variance.
Measurement of circulating plasma TNF-a concentrations demonstrated no signi®cant differences between the three groups (obese subjects: n 18, median 1.9, P25 0, P75 4.1 pgaml; obese diabetic subjects: n 10, median 2.7, P25 1.2, P75 4.1 pgaml; lean subjects: n 23, median 1.8, P25 0, P75 3.4 pgaml,Kruskal-Wallistest: P 0.34).Due to missing values and low power, an effect of obesity on TNF-a concentrations is not excluded. In addition, there was no substantial alteration of TNF-a concentrations in nine individuals, after a weight loss between 20±30 kg one year after gastroplasty (median 1.7, minimum 0.0, maximum 4.4 ngaml).
There was a positive correlation between the plasma concentrations of the soluble p60 and p80 TNF receptor (r 0.83, P`0.01). The correlation coef®cients between plasma TNF-a (n 51) and both soluble TNF receptors, in the whole study population, were not signi®cant (p80: r 0.25, P 0.08; p60: r 0.13, P 0.36). Only in the obese subjects without diabetes was a signi®cant correlation between p80 TNF receptor protein and TNF-a observed (r 0.70, P`0.01).
Discussion
The plasma concentrations of TNF-a and its two soluble receptors, are the result of cytokine production (Soluble) TNF-a receptors in obesity H Hauner et al by many tissues, including macrophages and monocytes. 18 Recent studies suggested that human fat cells are also a source of TNF-a, which is overexpressed in the obese state. 2, 3 However, it is still a matter of debate whether an increased adipose expression of this cytokine is re¯ected by elevated circulating TNF-a levels. Our data, although based on small groups, do not provide evidence for an increased out¯ow from adipose tissue, suggesting that the increased TNF-a production by fat cells is restricted to the adipose depots. This is also supported by a recent in vivo study in humans, where no arterio-venous difference in TNF-a concentration was found over a subcutaneous adipose tissue bed, arguing against a substantial release of TNF-a from this depot. 19 As a number of experimental studies suggested that TNF-a is implicated in the pathogenesis, if not the main cause, of obesity-linked insulin resistance, we also measured TNF-a concentrations in severely obese subjects with type 2 diabetes. We did not observe signi®cant differences in TNF-a concentrations, but this result must be cautiously interpreted in view of the low power. Only a few studies have been published so far on this issue. In a recent study by Pfeiffer et al, 20 men with NIDDM had slightly higher concentrations of circulating TNF-a than nondiabetic controls, whereas no difference was found between diabetic and nondiabetic women, who were clearly overrepresented in our study. No association was found between the TNF-a levels and the BMI of the subjects, whereas levels of TNF-a were positively correlated with serum triglyceride concentrations in that study. This increase may be a consequence of TNF-a action in adipose tissue, as TNF-a possesses an indirect lipolytic activity and impairs the catabolism of circulating triglyceriderich lipoproteins, due to a reduced expression of lipoprotein lipase. 13, 21, 22 In a recent study using the euglycaemic hyperinsulinaemic clamp technique, a weak association between TNF-a concentrations and glucose disposal rate was observed, which remained no longer signi®cant in a multivariate regression analysis. Only percent of desirable body weight turned out to be positively associated with serum TNF-a. 23 An interesting and novel ®nding is that the circulating levels of both TNF receptors are increased in severe obesity, independent of the presence of type 2 diabetes. To date, there is only one study on this issue showing a 6-fold elevation of the p80 TNF receptor protein in obese as compared to lean subjects.
14 In contrast to our results, these authors did not ®nd increased plasma concentrations of the soluble p60 TNF receptor. This discrepancy is dif®cult to explain. However, preliminary data from our laboratory also indicate that the mRNA levels for both receptor subtypes are increased in human adipose tissue, indicating an up-regulation of the whole TNF-a system. 15 It was also shown by other studies, that TNF-a itself is able to induce an increased expression of both receptor subtypes. 24, 25 TNF-a and TNF receptors are well known to be proteolytically cleaved. 16, 26 Whereas TNF-a also retains its biological activity in the soluble form, the physiological signi®cance of circulating soluble receptors is unknown. There is some evidence that soluble TNF receptors may function as circulating TNF-neutralizing binding proteins, 18 but one can also speculate that TNF-a and TNF receptor cleavage takes place primarily to reduce the local TNF signal transduction. At least in a study in obese fatafa rats, peripheral infusion of a recombinant soluble TNF-a receptorimmunoglobulin G chimeric protein, resulted in an amelioration of the reduced insulin sensitivity of the animals. 1 However, in a study carried out in type 2 diabetic subjects, neutralization of TNF-a by intravenous administration of an engineered human antiTNFa antibody, did not result in an improvement of insulin sensitivity and glucose tolerance. 10 Up to now, it is unclear whether the elevated circulating TNF receptor concentrations are due to increased expression and shedding by adipocytes. Further studies are required to examine if, and to what extent, fat cells are able to release TNF receptors.
Conclusion
Plasma concentrations of both soluble TNF receptor subtypes were found to be elevated in obesity, independent of the presence of diabetes. In contrast, these data do not provide evidence for a signi®cant role of adipose tissue as a source of circulating TNF-a. Future research should address the question whether the two soluble receptors play any physiological role in TNF action and how obesity is linked to the overexpression of both receptors.
